Holen Sie sich die Stockscreener-App
0.0002
9,900%
0.0003
Schlusskurs vom Vortag:
$0.0005
Offen:
$0.0002
24-Stunden-Volumen:
445
Relative Volume:
66.00
Marktkapitalisierung:
$N/A
Einnahmen:
-
Nettoeinkommen (Verlust:
$-66.00M
KGV:
-0.000377
EPS:
-0.53
Netto-Cashflow:
$-60.55M
1W Leistung:
+9,900%
1M Leistung:
-87.90%
6M Leistung:
-95.00%
1J Leistung:
-97.29%
1-Tages-Spanne:
$0.0002
$0.0203
1-Wochen-Bereich:
$0.0002
$0.0203
52-Wochen-Spanne:
$0.0002
$0.0203
Vaxxinity Inc Stock (VAXX) Company Profile
Compare VAXX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VAXX
Vaxxinity Inc
|
0.0002 | 0 | 0 | -66.00M | -60.55M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vaxxinity Inc Stock (VAXX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-09-08 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-04-27 | Eingeleitet | Evercore ISI | In-line |
Vaxxinity Inc Aktie (VAXX) Neueste Nachrichten
Critical Review: iBio (NYSE:IBIO) versus Vaxxinity (NASDAQ:VAXX) - Defense World
VAXX stock at $0.0001 intraday on 11 Feb 2026: critical risks for NASDAQ holders - Meyka
VAXX Vaxxinity, Inc. drops 99% to $0.0001 on NASDAQ 19 Jan 2026: outlook - Meyka
Analyzing Vaxxinity (NASDAQ:VAXX) and ProMetic Life Sciences (OTCMKTS:PFSCF) - Defense World
Vaxxinity Shares Plummet Amid Extreme Volatility - AD HOC NEWS
Analyzing Vaxxinity (NASDAQ:VAXX) & Actinium Pharmaceuticals (NYSE:ATNM) - Defense World
Tangible book value per share of Vaxxinity, Inc. – OTC:VAXX - TradingView
Hypercholesterolemia Pipeline Drugs Report 2025: MOA, Emerging Therapies, Clinical Trials, Treatment | DelveInsight - Barchart.com
Space Medicine Market Report 2025 | Innovative Space-Based Regenerative Medicine Aims to Enhance Human Health During Long-Duration Missions - 24matins.uk
Hypercholesterolemia Pipeline 2025: Innovative Clinical Advancements by 25+ Global Leaders – DelveInsight | Featuring companies such as Jiangsu HengRui Medicine Co., Ltd., Merck Sharp & Dohme LLC, Arr - Barchart.com
Dallas District Court Split in High-Stakes Stock Dispute - Inforney News
Migraine Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored | GlaxoSmithKline, Merck & Co., Inc., Pfizer, Bausch Health, Amgen, Abbvie Inc., AstraZeneca, Eli Lilly and Co - Barchart.com
Safety and immunogenicity of UB-612 heterologous booster in adults primed with mRNA, adenovirus, or inactivated COVID-19 vaccines: a randomized, active-controlled, Phase 3 trial - The Lancet
Top 6 Healthcare Stock Picks in 2025 - timothysykes.com
PCSK9 Inhibitors Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Statistics, Revenue, Pipeline, Therapies, and Companies by DelveInsight - The Globe and Mail
🐾 Pet of the Week: Meet Benny — Forney’s Frisbee-Loving Best Friend - Inforney News
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows - Pharmaceutical Technology
How a new kind of vaccine could lead to the eradication of Alzheimer's and dementia - New Scientist
Vaxxinity - The Pharma Letter
Study: Therapeutic Parkinson's vaccine safely inhibits alpha-synuclein clumps - Parkinson's News Today
A Potential Parkinson’s Treatment Has Promising Results - Time Magazine
Parkinson's Prevention May Include Tetanus Vaccination - Vax-Before-Travel
Vaxxinity’s Immunotherapy Meets Phase I Goals in Parkinson’s Patients - Inside Precision Medicine
Vaxxinity UB-312 Parkinson’s Trial Results Published in Nature Medicine - Yahoo Finance
Vaxxinity leaders detail retreat from 'abusive relationship' after 3 years on public market - Fierce Biotech
VAXX Stock Price and Chart — OTC:VAXX - TradingView
Terrell Breaks Ground On Northspur Development - Inforney News
Vaxxinity, Inc. (VAXX) Perplexes All, Surges 44% Amidst Delisting Decision - 富途牛牛
Why Is Vaxxinity (VAXX) Stock Up 39% Today? - InvestorPlace
What's Driving These Stocks Higher In After-hours? - RTTNews
Why Is Vaxxinity (VAXX) Stock Down 58% Today? - TradingView
Vaxxinity to voluntarily delist from Nasdaq - Investing.com
Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting - GlobeNewswire
Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates - Yahoo Finance
Parkinson's Drug Reduces Disease Markers in Breakthrough Trial - ScienceAlert
AD/PD 2024: Vaxxinity reveals Phase I success with Parkinson’s vaccine - Pharmaceutical Technology
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson’s Disease at AD/PD™ 2024 - Yahoo Finance
Peek inside the Space Coast vaccine lab working to create humanity’s moonshot - WFTV
Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published - Yahoo Finance
Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024 - GlobeNewswire
Vaxxinity, University of Florida join for work on Parkinson’s vaccine - Parkinson's News Today
Scrip Asks…What Does 2024 Hold For Biopharma? Part 4: Transformative Technology - Citeline News & Insights
Vaxxinity, University of Central Florida launch collaboration to advance medicines for use in space - Fierce Biotech
Vaccines show promise against common chronic diseases - Gavi, the Vaccine Alliance
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference - Stock Titan
Vaxxinity making vaccines to change the world - Labiotech.eu
Vaxxinity, Inc. (VAXX) stock price, news, quote and history - Yahoo Finance Singapore
Researchers return to Alzheimer's vaccines, buoyed by recent drug success - Reuters
Vaxxinity earnings missed by $9.89, revenue fell short of estimates - Investing.com UK
Mei Mei Hu - The World Economic Forum
Area fire departments fighting large grass fire north of Forney - Inforney News
Finanzdaten der Vaxxinity Inc-Aktie (VAXX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.90%
2.73%
Kapitalisierung:
|
Volumen (24h):